This is a working overview of TB-500, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-30. Anything still debated is marked as such rather than presented as settled.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
They also have great physical strength; a bear weighing 120 lb (54 kg) was observed flipping over flat rocks weighing 310 to 325 lb (141 to 147 kg) with a single foreleg. They move with a rhythmic, sure-footed gait and can run at speeds of up to 25–30 mph (40–48 km/h). American black bears have good eyesight and have been proven experimentally to be able to learn visual color discrimination tasks faster than chimpanzees and just as fast as domestic dogs. They are also capable of rapidly learning to distinguish different shapes, such as small triangles, circles and squares.
== Awards and honors == 2018 Elected fellow of the American Academy of Microbiology 2020 American Society for Microbiology Award for Research and Leadership in Clinical Microbiology Academy of Clinical Laboratory Physicians and Scientists Ellis S. Benson Award "40 Under 40" honoree by the American Society for Clinical Pathology
== Life cycle == The eggs hatch 4 to 19 days after the female oviposits. During the larval stage, the mealworms feed on vegetation and dead insects, and molt between each larval stage, or instar (9 to 20 instars). After the final molt, they pupate. The new pupa is whitish and turns brown over time. After 3 to 30 days, depending on environmental conditions such as temperature, it emerges as an adult beetle.
== Metabolism == The kynurenine pathway of tryptophan catabolism leads to nicotinamide adenine dinucleotide and supplies the nicotinic acid component of that cofactor. In this pathway, quinolinic acid is produced spontaneously from the intermediate semialdehyde as its amine cyclises with the aldehyde, losing a molecule of water:
==== Conceptual history ==== Frank Spotnitz explained that, despite their tendency of killing human abductees, the rebels can really be viewed as allies of mankind. He said in the commentary of "One Son" that the faceless rebels and the human race are the only two species of advanced civilization in the galaxy that have not been consumed by the black oil. Thus, he notes that at the end of the episode "humanity has lost, Mulder has lost, and the rebels in fact save the day, ultimately by stopping the delivery of Cassandra Spender to the aliens". The initial look of the rebels was created by special effects supervisor Tony Lindala, during the production of "Patient X". Spotnitz had a problem with the visual effects used for the rebels in "One Son", going so far as to say that the effects of them landing were among the worst ever created for the show. He noted that the effects were created on short notice, saying "It was one of those cases where you just run out of time, sorry to say." Spotnitz later said that the overall production values were fantastic, but that he wished he could have changed some things about the episode; in particular, he wished to have done the scene wherein one of the Syndicate members changes into an alien rebel differently.
Sources: en.wikipedia.org
== History == In the early 1900s it was discovered that a mixture containing calcium chloride, ammonium sulfate, and potassium bromate halved the amount of yeast needed to raise dough. These mixtures were generally known as mineral yeast foods or yeast nutrient salts. After they became popular among bakers, one patented yeast food was analyzed by Connecticut Agricultural Experiment Station chief chemist J. P. Street, who published in 1917 that it contained, "calcium sulphate, 25; ammonium chlorid, 9.7; potassium bromate, 0.3; sodium chlorid, 25; patent wheat flour, 40." They contain water conditioners, yeast conditioners, and dough conditioners.
Some enzymes need to go through a maturation process to be activated. A precursor (inactive state, better known as zymogen) is first synthesized, and then, by cutting some specific peptide bonds (enzymatic catalysis by hydrolytic selective split), its 3D conformation is highly modified into a catalytic functional status, obtaining the active enzyme. Proteolysis is irreversible and normally a non-specific process. The same activator can modulate different regulatory enzymes : once trypsin is activated, it activates many other hydrolytic enzymes. Proteolysis can also be fast and simple so the hydrolysis of a single peptide bond can be enough to change the conformation of the protein and build an active zone, allowing the interaction between the enzyme and the substrate, for instance, chymotrypsin activation (as it can be seen in the images). Many different types of proteins with different roles in metabolism are activated by proteolysis for big reasons:
==== Foreign policy ==== On June 12, 2017, U.S. senators agreed to legislation imposing new sanctions on Russia and Iran. The bill was opposed only by Sanders and Republican Rand Paul. He supported the sanctions on Russia, but voted against the bill because he believed the sanctions could endanger the Iran nuclear deal. In 2018, Sanders sponsored a bill and was joined by senators Chris Murphy (D–CT) and Mike Lee (R–UT) to invoke the 1973 War Powers Resolution to end US support for the Saudi-led military intervention in Yemen, which has resulted in hundreds of thousands of civilian casualties and "millions more suffering from starvation and disease". After the assassination of Jamal Khashoggi in October 2018 (which was ordered by Saudi Arabian crown prince Mohammad bin Salman, according to multiple intelligence agencies), his bill attracted bipartisan co-sponsors and support, and the Senate passed it by a vote of 56–41. The bill passed the House in February 2019 by a 247–175 vote and President Trump vetoed it in March, saying: "This resolution is an unnecessary, dangerous attempt to weaken my constitutional authorities, endangering the lives of American citizens and brave service members, both today and in the future." During the Gaza war, Sanders introduced several Joint Resolutions of Disapproval to block arms to Israel. All failed, but some Democrats voted for them. In November 2024, one such resolution garnered support from 18 senators. In April 2025, 15 senators supported another. In July 2025, 27 senators supported a resolution, a majority of Senate Democrats.
== Relationship to docking methods == The field of protein–protein interaction prediction is closely related to the field of protein–protein docking, which attempts to use geometric and steric considerations to fit two proteins of known structure into a bound complex. This is a useful mode of inquiry in cases where both proteins in the pair have known structures and are known (or at least strongly suspected) to interact, but since so many proteins do not have experimentally determined structures, sequence-based interaction prediction methods are especially useful in conjunction with experimental studies of an organism's interactome.
=== Cuticular color === Cuticular color (pigmentation of the cuticle) is a heritable component and varies from tan to black. In the mealworm beetle, evidence suggests that population level variation in cuticular color is linked to pathogen resistance in that darker individuals are more resistant to pathogens. A study found that two immune parameters related to resistance, haemocyte density and pre-immune challenge activity of phenoloxidase, were significantly higher in selection lines of black beetles compared to tan lines. Higher haemocyte density is likely indicative of a heightened immune response. There were no effects of gender on the immune traits. Cuticular color is dependent on melanin production, which requires phenoloxidase, an enzyme that is present in its inactive form inside haemocytes. This shows why darker insects have a heightened immune response and are more resistant to pathogens that invade the hemocoel via the cuticle. However, there was no significant difference in haemolymph antibacterial activity between black and tan lines, explained by how antimicrobial peptides are produced by haemocytes but are not involved in cuticular darkening. In T. molitor, the degree of cuticular melanization is a strong indicator of resistance to the entomopathogenic fungus Metarhizium anisopliae, which could be explained by the thicker and less porous cuticle displayed by darker insects compared to lighter ones.
Sources: en.wikipedia.org
=== Aplastic anemia === In the early 1960s, potassium perchlorate used to treat Graves' disease was implicated in the development of aplastic anemia—a condition where the bone marrow fails to produce new blood cells in sufficient quantity—in thirteen patients, seven of whom died. Subsequent investigations have indicated the connection between administration of potassium perchlorate and development of aplastic anemia to be "equivocable at best", which means that the benefit of treatment, if it is the only known treatment, outweighs the risk, and it appeared a contaminant poisoned the 13.
== Adverse effects == Side effects are rare. Reported adverse events include seizures, changes in color vision, blood clots, and allergic reactions such as anaphylaxis. Whether the risk of venous thromboembolism (blood clots) is increased is a matter of debate. The risk is mentioned in the product literature, and they were reported in post marketing experience. Despite this, and the inhibitory effect of tranexamic acid on blood clot breakdown, large studies of the use of tranexamic acid have not shown an increase in the risk of venous or arterial thrombosis, even in people who had previously experienced thrombosis under other circumstances.
LSD (lysergic acid diethylamide; lysergide) is a derivative of lysergic acid, which is obtained from the hydrolysis of ergotamine. Ergotamine is an alkaloid found in the fungus Claviceps purpurea (ergot), which primarily infects rye. LSD is both the prototypical psychedelic and the prototypical lysergamide. As a lysergamide, LSD contains both a tryptamine and phenethylamine group within its structure. Uniquely among psychedelics, LSD agonises dopamine receptors as well as serotonin receptors. Drugs like ALD-52 (1A-LSD), 1P-LSD, and 1V-LSD are prodrugs of LSD. Psilocin (4-HO-DMT) is the dephosphorylated active metabolite of the indole alkaloid psilocybin (4-PO-DMT) and a substituted tryptamine, which is produced by hundreds of species of psilocybin-containing mushrooms. Of the classical psychedelics, psilocybin has attracted the greatest academic interest regarding its ability to manifest mystical experiences, although all psychedelics are capable of doing so to variable degrees. 4-AcO-DMT (O-acetylpsilocin or psilacetin) is a synthetic acetylated analogue of psilocin and is a prodrug of psilocin similarly to psilocybin. Mescaline (3,4,5-trimethoxyphenethylamine) is a phenethylamine alkaloid found in various species of cacti, the best-known of these being peyote (Lophophora williamsii) and the San Pedro cactus (Echinopsis pachanoi, syn. Trichocereus macrogonus var. pachanoi). Mescaline has effects comparable to those of LSD and psilocybin.
Some endocrinologists and clinicians include the paracrine system as part of the endocrine system, but there is not consensus. Paracrines are slower acting, targeting cells in the same tissue or organ. An example of this is somatostatin which is released by some pancreatic cells and targets other pancreatic cells.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.